ScreenerHero

ANIK Anika Therapeutics, Inc.

NAS · US · Healthcare · Drug Manufacturers - Specialty & Generic · anika.com
19.53USD+2.14%Mkt Cap: 261.37M $P/E: —

Anika Therapeutics, Inc., a joint preservation company, focuses on early intervention orthopedics in the United States, Europe, and internationally. The company offers osteoarthritis (OA) pain management products and ser…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
Merck KGaA
$66.23BUSDP/E 25.7
TAK
Takeda Pharmaceutical Company Limited
$58.68BUSD
TEVA
Teva Pharmaceutical Industries Limited
$45.70BUSDP/E 65.3
GALD
Galderma Group AG
$43.27BUSDP/E 56.1
HLN
Haleon plc
$39.67BUSDP/E 18.4
SDZ
Sandoz Group AG
$34.93BUSDP/E 60.5
HLN
Haleon plc
$32.73BUSDP/E 19.0
ZTS
Zoetis Inc.
$29.57BUSDP/E 11.8
ZOE
Zoetis Inc.
$28.56BUSDP/E 12.2
UTHR
United Therapeutics Corporation
$23.38BUSDP/E 19.5
VTRS
Viatris Inc.
$20.09BUSD
SOBI
Swedish Orphan Biovitrum AB (publ)
$14.43BUSDP/E 112.9
NBIX
Neurocrine Biosciences, Inc.
$14.58BUSDP/E 21.0
IPN
Ipsen S.A.
$12.99BUSDP/E 23.5
ELAN
Elanco Animal Health Incorporated
$11.17BUSD
RDY
Dr. Reddy's Laboratories Limited
$10.22BUSDP/E 27.9
KRK
Krka, d. d.
$8.66BUSDP/E 19.3
ALKS
Alkermes plc
$6.95BUSDP/E 109.1
HIMS
Hims & Hers Health, Inc.
$6.89BUSD
AMRX
Amneal Pharmaceuticals, Inc.
$6.84BUSDP/E 40.1

Key Statistics

Company
Market Cap261.37M USD
Enterprise Value242.72M USD
Revenue (TTM)120.65M USD
Gross Profit63.81M USD
Net Income (TTM)-10.88M USD
Revenue/Share8.69 USD
Last Price19.53 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees235
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)20.13
PEG2.08
EV/EBITDA79.84
EV/Revenue2.01
P/S2.12
P/B1.86
EPS (TTM)-0.22
EPS (Forward)0.95
52W Range
8.67076% of range22.88
52W High22.88 USD
52W Low8.670 USD
Profitability
Gross Margin56.56%
Oper. Margin11.43%
EBITDA Margin2.52%
Profit Margin-9.64%
ROE-7.58%
ROA-5.72%
Growth
Revenue Growth15.60%
Earnings Growth—
Cash Flow & Leverage
Operating CF11.19M USD
CapEx (TTM)6.83M USD
FCF Margin2.54%
FCF Yield1.17%
Net Debt-13.16M USD
Net Debt/EBITDA-4.33
Balance Sheet
Debt/Equity0.18
Current Ratio4.48
Quick Ratio3.05
Book Value/Sh10.26 USD
Cash/Share2.87 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.5 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)23.00 USD
Upside (mean)+17.8%
Target Range23.00 USD – 23.00 USD
# Analysts2
Ownership
Shares Out.13.38M
Float11.29M
Insiders6.40%
Institutions93.64%
Short Interest
Short Ratio3.7d
Short % Float3.74%
Short % Out.2.85%
Shares Short381.38K
Short (prev mo.)337.21K
Technical
SMA 5020.48 (-4.7%)
SMA 20015.08 (+29.5%)
Beta0.21
S&P 52W Chg16.45%
Avg Vol (30d)97.58K
Avg Vol (10d)96.53K
Technical Indicators
RSI (14)44.9
MACD-0.2014
MACD Signal0.0137
MACD Hist.-0.2151
BB Upper21.69 USD
BB Middle20.32 USD
BB Lower18.95 USD
BB Width13.50%
ATR (14)0.8198 USD
Vol Ratio (20d)2.19x